<DOC>
	<DOCNO>NCT00006509</DOCNO>
	<brief_summary>The purpose study see 2 study vaccine , ALVAC-HIV ( vCP1452 ) gp160 MN/LAI-2 , safe effective boost body 's attack HIV HIV-positive patient . HIV-infected patient treat anti-HIV drug long time may weaken immune response . One way strengthen response may safe effective vaccine , boost immune response specific HIV .</brief_summary>
	<brief_title>A Study Safety Effectiveness HIV Vaccine HIV-Positive Patients Receiving Anti-HIV Drugs Least 2 Years</brief_title>
	<detailed_description>HIV-infected patient treated antiretroviral therapy prolong period time may show decreased level HIV-specific immune response . In patient , prime-boost vaccine strategy may induce humoral cell-mediated immunity . The hypothesis study vaccine strategy select safe immunogenic patient population test . Patients continue antiretroviral medication throughout course study . All patient receive intramuscular injection ALVAC-HIV ( vCP 1452 ) recombinant soluble gp160 MN/LAI-2 Days 0 , 30 , 90 , 180 . Patients monitor safety 30 minute immunization telephone contact within 72 hour vaccination . In addition , patient record adverse event diary . Patients regular physical exam , pregnancy test , blood drawn virologic immunologic assessment . The induction HIV-specific response measure .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIVpositive . Have viral load ( amount HIV blood ) less 50 copies/ml . Have take antiHIV drug least 2 year . Are already participate ongoing clinical trial Aaron Diamond AIDS Research Center . Are least 19 year old . Practice abstinence use 2 barrier method birth control , men woman able child . Exclusion Criteria Patients eligible study : Have HIV infection spread body even though take antiHIV drug . Are breastfeed . Are pregnant . Are allergic egg and/or neomycin . Show evidence poor immune response .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Recombinant Proteins</keyword>
	<keyword>HIV Envelope Protein gp160</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>HIV Therapeutic Vaccine</keyword>
</DOC>